American Society of Hirudotherapy

Treatment of dabigatran intoxication in critically ill patients with Acute Kidney Injury: The role of Sustained Low-Efficiency Dialysis

Case series published in The International journal of artificial organs (2023)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteraturePacchiarini et al. · The International journal of artificial organs, 2023

Abstract

The use of dabigatran in patients with non-valvular atrial fibrillation (AF) has widely increased in the last decades, due to its positive effects in terms of safety/efficacy. However, because of the risk of major bleeding, a great degree of attention has been suggested in elderly patients with multiple comorbidities. Notably, dabigatran mainly undergoes renal elimination and dose adjustment is recommended in patients with Chronic Kidney Disease (CKD). In this regard, the onset of an abrupt decrease of kidney function may further affect dabigatran pharmacokinetic profile, increasing the risk of acute intoxication. Idarucizumab is the approved antagonist in the case of dabigatran-associated major bleeding or concomitant need of urgent surgery, but its clinical use is limited by the lack of data in patients with Acute Kidney Injury (AKI). Thus, the early start of Extracorporeal Kidney Replacement Therapy (EKRT) could be indicated to remove the drug and to reverse the associated excess anticoagulation. Sustained Low-Efficiency Dialysis (SLED) could represent an effective therapeutic option to reduce the dabigatran plasma levels rapidly while avoiding post-treatment rebound. We present here a case series of three AKI patients with acute dabigatran intoxication, effectively and safely resolved with a single SLED session.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAgedDabigatranHybrid Renal Replacement TherapyCritical IllnessHemorrhageAcute Kidney InjuryAnticoagulants

Summary

Three critically ill patients with acute kidney injury and dabigatran intoxication were effectively and safely treated with a single session of sustained low-efficiency dialysis, which rapidly lowered plasma dabigatran levels without post-treatment rebound.

Context

This case series describes three patients with Acute Kidney Injury and acute dabigatran (a direct thrombin/factor IIa inhibitor) intoxication whose excess anticoagulation was reversed by a single session of Sustained Low-Efficiency Dialysis, after the abstract notes that the approved antidote idarucizumab lacks data in AKI. It is a reminder of the bleeding hazards and reversal challenges of modern pharmacologic anticoagulants, the backdrop against which the medicinal leech's locally acting secretome (e.g. hirudin, also a thrombin inhibitor) is studied as a drug-discovery source. Caveat: this is a small, uncontrolled case series about dialytic drug removal in a hospital setting; it concerns oral anticoagulant management, mentions neither leeches nor hirudotherapy, and should not be read as evidence for or against leech therapy.

Citation

Reference (Vancouver style)

Pacchiarini MC, Regolisti G, Greco P, Di Motta T, Benigno GD, Delsante M, et al. Treatment of dabigatran intoxication in critically ill patients with Acute Kidney Injury: The role of Sustained Low-Efficiency Dialysis. Int J Artif Organs. 2023;46(10-11):574-580. doi:10.1177/03913988231204516. PMID: 37853619

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.